Posts Tagged ‘california’
Dog DNA tests are on the risebut are they reliable? – National Geographic
Breed is a surprisingly complicated question, says Halie Rando, an assistant professor of computer science at Smith College who led the research. A dogs genetics may point to one breed, she says. But widely accepted breed definitions were defined in a time before DNA analysis, and Rando says that genetic testing can sometimes clash with pet owners preconceived notions about their dogs.
Even experienced humans, it turns out, are terrible at identifying breed by sight: In a recent study of 459 shelter dogs at two humane societies in Arizona and California, DNA analysis pinpointed found 125 distinct breeds, including five percent that were purebred. Nonetheless, neither the scientists nor the experienced shelter workers were able to reliably identify mixed-breed dogs, which made up nearly 90 percent of the canine cohort.
Mixed breeds can prove tricky even with DNA dataand since genetic testing relies on information about the genes of dogs with identifiable breeds, a DNA test is only as good as its genetic dataset.
As a consumer, you might value a company that is more transparent and has a diverse [DNA] panel, says Greene. He encourages consumers to do their research before submitting a sampleand double-check that the panel used by the testing company includes the breeds you suspect might be in the mix.
Even if you do get accurate information about your dogs breed, it might not be as linked to its behavior as you might think. A 2022 genetic analysis of more than 2,000 purebred and mixed-breed dogs found behavior was linked more closely to individual dogs than breeds, concluding that dog breed is generally a poor predictor of individual behavior.
Excerpt from:
Dog DNA tests are on the risebut are they reliable? - National Geographic
CRISPR Therapeutics to Present at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting – GlobeNewswire
ZUG, Switzerland and BOSTON, April 01, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics(Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced an oral presentation at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting, taking place May 7 11, 2024, in Baltimore, MD and virtually.
Title: Development of an In Vivo Non-Viral Ocular Editing Platform and Application to Potential Treatments for Glaucoma Session Type: In-Person Oral Presentation Session Title: Ophthalmic and Auditory: Delivery Innovations Abstract Number:87 Location: Room 318 323 Session Date and Time: Wednesday, May 8, 2024, 1:30 p.m. 3:15 p.m. ET
Abstracts will be released to the public on April 22, 2024, at 4:30 p.m. ET at https://annualmeeting.asgct.org/. The data are embargoed until 6:00 a.m. ET on the presentation day, Wednesday May 8, 2024. A copy of the presentation will be available at http://www.crisprtx.com once the presentation concludes.
About CRISPR Therapeutics Since its inception over a decade ago, CRISPR Therapeutics has transformed from a research-stage company advancing programs in the field of gene editing, to a company with a diverse portfolio of product candidates across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, cardiovascular and rare diseases. The Nobel Prize-winning CRISPR science has revolutionized biomedical research and represents a powerful, clinically validated approach with the potential to create a new class of potentially transformative medicines. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic partnerships with leading companies including Bayer and Vertex Pharmaceuticals. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Boston, Massachusetts and San Francisco, California, and business offices in London, United Kingdom. To learn more, visit http://www.crisprtx.com.
Investor Contact: Susan Kim +1-617-307-7503 susan.kim@crisprtx.com
Media Contact: Rachel Eides +1-617-315-4493 rachel.eides@crisprtx.com